Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms...

New therapies come slowly for type 1 diabetes, so the approval of teplizumab by the USA Food and Drug Administration (FDA) marks a milestone....

World Diabetes Day (Nov 14) this year marks the midpoint of the 3-year Access to Diabetes Care campaign, initiated last year in the centenary...

Our analysis suggests that in people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed the rate of eGFR decline and reduced UACR...

A validated treatment selection algorithm for SGLT2 inhibitor and DPP-4 inhibitor therapies can support decisions on optimal treatment for people with type 2...

SGLT2 and DPP4 inhibitor therapies are two classes of glucose-lowering treatment for people with type 2 diabetes. SGLT2 inhibitors are recommended by clinical treatment...

Despite declining lifetime risk and improvements in life expectancy for those with type 2 diabetes in many high-income jurisdictions, the burden of type 2...

During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in...

Explore the current issue of The Lancet Diabetes & Endocrinology, a monthly journal focussed on diabetes, endocrinology, and...

Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular disease. The...